Haleon PLC Sponsored ADR
HLN Healthcare Drug Manufacturers Specialty & Generic
Haleon PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $14.5 billion, up 1.33% from fiscal 2024. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow HLN
Haleon PLC Sponsored ADR (HLN) P/E ratio
As of 16 October 2026, Haleon PLC Sponsored ADR (HLN) trades at a P/E ratio of 22.6×. Over the past ten years it has ranged from 19.4× (June 2026) to 26.1× (September 2024); the current reading is higher than 73% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 19.2× and in line with the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 22.5× | 5.97% |
| FY2024 | 21.3× | 4.19% |
| FY2023 | 20.4× | 0.00% |
| FY2022 | 20.4× | 0.00% |
| FY2021 | 20.4× | 0.00% |
| FY2020 | 20.4× | 0.00% |
| FY2019 | 20.4× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2024 | 23.6× | 15.55% |
| Mar 2024 | 20.4× | 0.00% |
| Sep 2023 | 20.4× | 0.00% |
| Jun 2023 | 20.4× | 0.00% |
| 1 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VTRS Viatris Inc. compare | n/m |
| ELAN Elanco Animal Health Incorporated compare | n/m |
| ZTS Zoetis Inc. compare | 13.0× |
| UTHR United Therapeutics Corporation compare | 17.6× |
| NBIX Neurocrine Biosciences, Inc. compare | 19.2× |
| HLN Haleon PLC Sponsored ADR | 22.6× |
| TAK Takeda Pharmaceutical Co. compare | 29.6× |
| RDY Dr. Reddy's Laboratories Ltd compare | 32.9× |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 65.9× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)